Mortality rate with appropriate empiric treatment
|
0.013
|
0.012
|
0.014
|
Edelsberg et al. [13]
|
Mortality rate with inappropriate empiric antibiotic
|
0.095
|
0.086
|
0.105
|
Edelsberg et al. [13]
|
Duration of empiric therapy
|
3 days
|
3 days
|
3 days
|
Assumption
|
Total LOS for IAAT (inc. empiric therapy)
|
6.9 days
|
6.8 days
|
7 days
|
Edelsberg et al. [13]
|
Total LOS for IIAT (inc. empiric therapy)
|
11.5 days
|
11.3 days
|
11.9 days
|
Edelsberg et al. [13]
|
Health utility for survivors
|
0.85
|
0.70
|
1.00
|
Assumption based on Jansen et al. [25]
|
Discount rate
|
3.0%
|
3.0%
|
3.0%
|
AMCP [26]
|
Hospital cost per day (average)
|
$2558.55
|
$2046.84
|
$3070.26
|
HCUP [27]
|
Drug acquisition costs per day
| | |
Ceftolozane/tazobactam plus metronidazole
|
$253.20
|
Analy$ource [29]
|
Aztreonam
|
$84.24
|
Analy$ource [29]
|
Cefepime
|
$23.04
|
Analy$ource [29]
|
Ceftazidime
|
$36.66
|
Analy$ource [29]
|
Ceftriaxone
|
$6.40
|
Analy$ource [29]
|
Ciprofloxacin
|
$5.26
|
Analy$ource [29]
|
Doripenem
|
$125.22
|
Analy$ource [29]
|
Imipenem
|
$73.12
|
Analy$ource [29]
|
Levofloxacin
|
$6.24
|
Analy$ource [29]
|
Meropenem
|
$81.51
|
Analy$ource [29]
|
Piperacillin/tazobactam
|
$43.08
|
Analy$ource [29]
|
Tigecycline
|
$238.34
|
Analy$ource [29]
|
Salvagea
|
$164.31
|
Analy$ource [29]
|
Health care expenditure incurred per year
| | |
<25 years
|
$477
|
Basu [18]
|
25 to 34 years
|
$790
|
Basu [18]
|
35 to 44 years
|
$947
|
Basu [18]
|
45 to 54 years
|
$1422
|
Basu [18]
|
55 to 64 years
|
$2106
|
Basu [18]
|
65 to 74 years
|
$2758
|
Basu [18]
|
75 years and above
|
$3100
|
Basu [18]
|